Daya CNS’s product pipeline comprises non-opioid, disease modifying medications for the treatment for neuropathies, arthritis, and drug addiction.
OPPORTUNITY AND UNMET NEED
Neuropathic pain (chemotherapy induced neuropathy, diabetic neuropathy, fibromyalgia, etc.), not only impairs quality of life, but ominously leads to disruption and discontinuation of cancer chemotherapy. Notwithstanding the fact opioid and methamphetamine abuse present a major socioeconomic burden, these drugs of abuse produce large number of deaths every year. Hence, new medications that will replace opioids are in high demand, and revenue for such medications is estimated to be in billions.
is a potent, disease modifying non-opioid medication for the treatment of chronic pain.
DDD - 024
Daya has discovered a proprietary platform technology comprising
three small molecule scaffolds that do NOT display any opioid activity.